RU2017124141A - Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение - Google Patents
Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение Download PDFInfo
- Publication number
- RU2017124141A RU2017124141A RU2017124141A RU2017124141A RU2017124141A RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A RU2017124141 A RU 2017124141A
- Authority
- RU
- Russia
- Prior art keywords
- high affinity
- condition
- fusion protein
- administering
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Слитый белок, содержащий высокоаффинный Fc-связывающий домен и высокоаффинный CD3-связывающий домен.
2. Слитый белок по п.1, где указанный высокоаффинный Fc-связывающий домен выбран из группы, состоящей из эктодомена CD64, высокоаффинного варианта CD16 и фрагмента антитела с высокой аффинностью к Fc человека.
3. Слитый белок по п.1, где высокоаффинный CD3-связывающий домен представляет собой scFv моноклонального антитела против OKT3.
4. Слитый белок по п.3, где указанное моноклональное антитело против OKT3 представляет собой dhOKT3.
5. Фармацевтическая композиция, содержащая слитый белок по пп. 1-4 и фармацевтически приемлемый эксципиент.
6. Способ терапевтического лечения состояния у нуждающегося в этом индивидуума, включающий введение указанному индивидууму терапевтически эффективного количества фармацевтической композиции по п.5.
7. Способ по п.6, дополнительно включающий введение терапевтического антитела против по меньшей мере одного антигена поверхности клетки, свидетельствующего об указанном состоянии.
8. Способ по п.7, где указанное антитело содержит Fc-область, по существу, схожую с IgG4 человека.
9. Способ по п.6, где указанное состояние выбрано из группы, состоящей из злокачественного новообразования, воспалительного заболевания, аутоиммунного заболевания, отторжения трансплантата и инфекции.
10. Способ профилактического лечения состояния у нуждающегося в этом индивидуума, включающий введение указанному индивидууму профилактически эффективного количества фармацевтической композиции по п.5.
11. Способ по п.10, дополнительно включающий введение вакцины против указанного состояния.
12. Способ по п.10, где указанное состояние представляет собой злокачественное новообразование.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017124141A true RU2017124141A (ru) | 2019-01-10 |
| RU2017124141A3 RU2017124141A3 (ru) | 2019-06-19 |
| RU2725807C2 RU2725807C2 (ru) | 2020-07-06 |
Family
ID=56108081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017124141A RU2725807C2 (ru) | 2014-12-08 | 2015-12-08 | Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170362299A1 (ru) |
| EP (1) | EP3230311B1 (ru) |
| JP (2) | JP7095992B2 (ru) |
| KR (1) | KR102654033B1 (ru) |
| CN (1) | CN107108718B (ru) |
| AU (1) | AU2015360642B2 (ru) |
| CA (1) | CA2968987C (ru) |
| NZ (1) | NZ732073A (ru) |
| RU (1) | RU2725807C2 (ru) |
| SG (1) | SG11201704124YA (ru) |
| WO (1) | WO2016094456A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| CN112512573A (zh) * | 2018-05-23 | 2021-03-16 | 百提威生技股份有限公司 | 双特异性t细胞衔接蛋白及其用途 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| AU2021301788A1 (en) * | 2020-06-30 | 2023-01-19 | Gaia Biomedicine Inc. | Method for stabilizing binding of NK cell and antibody, and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Change of direction of cellular immunity by chimera receptors |
| ES2176574T3 (es) * | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| EA004107B1 (ru) * | 1998-08-11 | 2003-12-25 | Айдек Фармацевтикалс Корпорэйшн | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US7045605B2 (en) * | 2001-06-01 | 2006-05-16 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| WO2004076621A2 (en) * | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co. Ltd. | Compositions of nucleic acids for treating and detecting influenza virus |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| NZ546173A (en) * | 2003-10-16 | 2009-04-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
| US8101722B2 (en) * | 2004-02-16 | 2012-01-24 | Micromet Ag | Less immunogenic binding molecules |
| US20080003225A1 (en) * | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| AU2008209436A1 (en) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble Fc gamma R1a for reducing inflammation |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| PT2654790T (pt) | 2010-12-22 | 2019-05-16 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpo modificado com semivida melhorada |
| JP2015505843A (ja) * | 2011-12-15 | 2015-02-26 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
| WO2013128027A1 (en) * | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
-
2015
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 US US15/532,770 patent/US20170362299A1/en active Pending
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en active Application Filing
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en unknown
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en active Active
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active IP Right Grant
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ732073A (en) | 2019-04-26 |
| CA2968987C (en) | 2022-05-10 |
| EP3230311B1 (en) | 2022-01-26 |
| KR20170089003A (ko) | 2017-08-02 |
| RU2017124141A3 (ru) | 2019-06-19 |
| JP2018502068A (ja) | 2018-01-25 |
| US20220235115A1 (en) | 2022-07-28 |
| AU2015360642A1 (en) | 2017-06-08 |
| KR102654033B1 (ko) | 2024-04-02 |
| US20170362299A1 (en) | 2017-12-21 |
| SG11201704124YA (en) | 2017-06-29 |
| WO2016094456A1 (en) | 2016-06-16 |
| CN107108718A (zh) | 2017-08-29 |
| CN107108718B (zh) | 2022-07-22 |
| EP3230311A1 (en) | 2017-10-18 |
| JP7095992B2 (ja) | 2022-07-05 |
| CA2968987A1 (en) | 2016-06-16 |
| JP2021035994A (ja) | 2021-03-04 |
| AU2015360642B2 (en) | 2019-04-04 |
| EP3230311A4 (en) | 2018-05-30 |
| RU2725807C2 (ru) | 2020-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017124141A (ru) | Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
| JP2018508483A5 (ru) | ||
| JP2016529229A5 (ru) | ||
| JP2015533795A5 (ru) | ||
| EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2017113019A5 (ru) | ||
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2016531907A5 (ru) | ||
| JP2023011710A (ja) | Ｓ．ａｕｒｅｕｓ溶血素ａ毒素に対するヒト抗体 | |
| RU2016107426A (ru) | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета | |
| JP2020536109A5 (ru) | ||
| HRP20220637T1 (hr) | Protutijela anti-komplementa c1s i njihova upotreba | |
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| MX2009011996A (es) | Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica. | |
| AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
| JP2017531642A5 (ru) | ||
| JP2016502515A5 (ru) |